JointHealth™ express – ACE National Survey on Arthritis Self-Advocacy (For Patients)

Arthritis Consumer Experts (ACE) is conducting a National Survey on Self-Advocacy. Please support this initiative by sharing with your patients. The link below offers more information, including the survey link: Self Advocacy Survey […]

Read More…


Updated Biosimilar Fact Sheet

June 24 Biosimilar-Fact-Sheet […]

Read More…


Updated Recommendations From the Vaccine Clinical Advisory Group

The Vaccine Clinical Advisory Group has published updated Recommendations on Exceptions to Extended Dose Intervals for COVID-19 vaccines. Please note that this is not yet government policy. To review the entire report, click […]

Read More…


New Feature on SADIE: The Exceptional Access Program Digital Assistant – Now With Delegates!

The Ministry of Health continues to modernize the Exceptional Access Program (EAP) and transition away from fax-based processes by December 31, 2021. As the next major step forward, you can now assign delegates in SADIE who can create and […]

Read More…


Attestation Forms to Confirm Vaccine Eligibility Not Required

The Ministry of Health has communicated to all 34 public health units that attestation forms and doctors’ notes are not required to confirm vaccine eligibility. This is in response to the OMA advocating to the government that […]

Read More…


Information for Switching Actemra IV Patients to Subcutaneous

The ORA has prepared an important communication piece to explain this matter. You may view it here: Important information for switching Actemra IV patients to subcutaneous […]

Read More…


New MOH Email Information Service

New MOH Email Information Service The Ontario Claims Services Branch has introduced subscription services for physicians and other health-care providers to receive email communications starting this month. This is a new resource to […]

Read More…


Actemra IV Supply Update

The following notice was posted by the CRA on April 7, 2021: Dear CRA members, We would like to provide an update on the current situation concerning ACTEMRA IV in Canada. The CRA has been monitoring stock levels […]

Read More…


Updated Biosimilar Fact Sheet – New LU Codes

The Ministry recently issued new LU Codes for etanercept and adalimumab biosimilars, effective March 29, 2021. The ORA has updated its Biosimilar Fact Sheet to reflect these changes. To download the form, please […]

Read More…


OMA COVID-19 Patient Assessment Tool For Physicians

The OMA has made available a patient assessment tool for physicians. To access this resource, please visit this link: OMA Covid-19 Patient Assessment Tool For Physicians (March 2021) […]

Read More…